- Home
- NA vs RVPH Comparison
NA vs RVPH Comparison
Compare NA & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- RVPH
- Stock Information
- Founded
- NA 2019
- RVPH 2006
- Country
- NA China
- RVPH United States
- Employees
- NA N/A
- RVPH N/A
- Industry
- NA Semiconductors
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- NA Technology
- RVPH Health Care
- Exchange
- NA Nasdaq
- RVPH Nasdaq
- Market Cap
- NA 32.3M
- RVPH 33.4M
- IPO Year
- NA 2022
- RVPH N/A
- Fundamental
- Price
- NA $8.76
- RVPH $1.56
- Analyst Decision
- NA
- RVPH Strong Buy
- Analyst Count
- NA 0
- RVPH 4
- Target Price
- NA N/A
- RVPH $15.33
- AVG Volume (30 Days)
- NA 240.6K
- RVPH 4.3M
- Earning Date
- NA 09-18-2024
- RVPH 11-14-2024
- Dividend Yield
- NA N/A
- RVPH N/A
- EPS Growth
- NA N/A
- RVPH N/A
- EPS
- NA N/A
- RVPH N/A
- Revenue
- NA $6,991,446.00
- RVPH N/A
- Revenue This Year
- NA N/A
- RVPH N/A
- Revenue Next Year
- NA N/A
- RVPH N/A
- P/E Ratio
- NA N/A
- RVPH N/A
- Revenue Growth
- NA N/A
- RVPH N/A
- 52 Week Low
- NA $2.75
- RVPH $0.60
- 52 Week High
- NA $47.50
- RVPH $5.67
- Technical
- Relative Strength Index (RSI)
- NA 52.67
- RVPH 48.70
- Support Level
- NA $6.67
- RVPH $1.25
- Resistance Level
- NA $10.42
- RVPH $4.28
- Average True Range (ATR)
- NA 1.94
- RVPH 0.47
- MACD
- NA -0.18
- RVPH -0.01
- Stochastic Oscillator
- NA 29.07
- RVPH 14.65
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.